Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. - Wikidata - wikimedia - TriplyDB

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

http://www.wikidata.org/entity/Q39632069

about

Calcium channel blockers for primary Raynaud's phenomenon Drug interventions versus placebo for the treatment of Raynaud’s phenomenon: generic protocol Calcium channel blockers for primary Raynaud's phenomenon Oral vasodilators for primary Raynaud's phenomenon Calcium channel blockers for primary Raynaud's Phenomenon My approach to the treatment of scleroderma The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context.The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial Auricular electroacupuncture reduces frequency and severity of Raynaud attacks.Raynaud's phenomenon (primary).Association of gender with clinical expression, quality of life, disability, and depression and anxiety in patients with systemic sclerosis.Disease severity and domain-specific arthritis self-efficacy: relationships to pain and functioning in patients with rheumatoid arthritis.Reliability and validity of the delta finger-to-palm (FTP), a new measure of finger range of motion in systemic sclerosis Registry evaluation of digital ulcers in systemic sclerosis.Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.Treatment expectation for pain coping skills training: relationship to osteoarthritis patients' baseline psychosocial characteristics.Needs and preferences regarding health care delivery as perceived by patients with systemic sclerosis Clinical, functional and health-related quality of life correlates of clinically significant symptoms of anxiety and depression in patients with systemic sclerosis: a cross-sectional survey.Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging: a 12-week randomized double-blind placebo controlled trial.Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis.Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis Development and validation of a scale for mouth handicap in systemic sclerosis: the Mouth Handicap in Systemic Sclerosis scale.Symptom Interference Severity and Health-Related Quality of Life in Pulmonary Arterial Hypertension.Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials.Effectiveness and safety of oxycodone/naloxone in the management of chronic pain in patients with systemic sclerosis with recurrent digital ulcers: two case reports.The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis Therapeutic options for digital ulcers in patients with systemic sclerosis.A standardized core set for systemic sclerosis clinical trials. First step in development of combined response index T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease.Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry.Development of a provisional core set of response measures for clinical trials of systemic sclerosis.Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial The challenge of scleroderma ulcers.Sildenafil increases digital skin blood flow during all phases of local cooling in primary Raynaud's phenomenon Validation of the scleroderma health assessment questionnaire and quality of life in English and Chinese-speaking patients with systemic sclerosis.Negative affect in systemic sclerosis.Infrared-monitored cold response in the assessment of Raynaud's phenomenon.Endothelial Dysfunction and Nailfold Videocapillaroscopy Pattern as Predictors of Digital Ulcers in Systemic Sclerosis: a Cohort Study and Review of the Literature.Behaviour change interventions for the management of Raynaud's phenomenon: a systematic review protocol.Clinical Trial Design Issues in Systemic Sclerosis: an Update.

P2860

Q24186106-5F2F7DE7-FA50-4E44-B970-A97F3F5A458F Q24188181-EA8CFD6B-498B-457E-959C-A4310B79CCAD Q24200938-B0600606-DA00-4761-AD14-7ECD7AA466BE Q24202210-A670950A-8DC9-4002-87E4-D07253109A8E Q24242837-949DC29A-13FC-4BC8-9F63-CF64E3A97AD1 Q24618843-AFB7F3A4-9F20-4857-AF4F-6C78ED9B426E Q30542602-8AAEB9EF-4767-4E06-824F-18F20BD88464 Q33724464-64BB6458-2FE6-4868-A793-4742E880C110 Q33822485-17583284-420E-4260-8143-469C4DEF6F94 Q33845502-1E88F5F6-EF1E-48B5-9751-8634A249F0AB Q33847277-DE5D6777-D5AE-46D4-B386-42AB2A114D02 Q33910523-6DED57E4-5329-4C7B-A55B-4B8A989EA525 Q34109827-AA9A11DB-D074-4C33-9B82-C205FE601DAE Q34123635-6BA2939C-FFB0-4CA7-A48C-A4CED02CC59B Q34409802-12CDD59F-BF2D-4278-9EC8-90516E9CABA9 Q34796377-3D5A0A21-42BA-4A0E-9D3C-BDDC873AFA83 Q35004679-87197EA5-8922-49A9-A103-5AC2DC5A93ED Q35109082-BEA46447-9148-41EF-82E6-C2697F10CACC Q35256824-E9A2F6D6-D77C-4CEA-8155-14ED2ADF6A9D Q35851777-DEA78619-5A75-4D91-A325-771B04340AD9 Q35977294-C639B92B-5D03-4D25-8467-1C6A534FCCB4 Q36171844-81782A36-7EC0-4E67-8B29-2CF77B5C0E72 Q36421934-F85C1DEB-D2DA-4408-AB98-C969BF70A86E Q36488075-47A374E6-126F-4375-8FD6-21A7C07B6364 Q36702532-C3D0E91C-63ED-48E8-826E-9CA7A226CF74 Q36758822-FFE1E9AB-0A32-4308-B5CE-7F64ABFFB684 Q36835012-3BBE38F6-0DFF-4D61-A776-96C83B476638 Q36869412-8F44C88E-7594-45E8-B6E5-3A47DE41EA31 Q37143961-8A9C1E3A-172D-474B-8BCE-6B6EE2BA53C4 Q37282479-88A6BE2D-8148-450B-9EA7-C456207BE0C0 Q37460792-9D11C3BB-6B3C-49D0-AA3D-FCD92EE32EA5 Q37460808-61E4F837-47E1-4574-B172-4D5B60B83EA4 Q37500626-5CB2F758-5C23-4385-AB6C-EEF34125653D Q37724814-9F31FA2A-012C-498B-B277-16C19E3C80DD Q38019624-008E6B4C-B9BA-4516-9294-41B2D05260FE Q38144762-D5C3CAAC-956A-48A7-9402-B55321443181 Q38455289-232EB2C3-526A-4CAE-BD19-AA8D8D707A4A Q38542662-7F08EA00-6685-4910-A765-86135C866578 Q38638665-4D78F40A-C1A7-4B9B-A04D-4F9E6448A00C Q38825869-E8550D28-57FC-42CB-9748-73F9568E9974

P2860

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

http://www.wikidata.org/entity/Q39632069

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Measuring disease activity and ...... erma and Raynaud's phenomenon.

@en

Measuring disease activity and ...... erma and Raynaud's phenomenon.

@nl

type

label

Measuring disease activity and ...... erma and Raynaud's phenomenon.

@en

Measuring disease activity and ...... erma and Raynaud's phenomenon.

@nl

prefLabel

Measuring disease activity and ...... erma and Raynaud's phenomenon.

@en

Measuring disease activity and ...... erma and Raynaud's phenomenon.

@nl

P1433

Q39632069-A3FDE69A-8005-4D10-A5ED-C4ADA2A358E8

P1476

Q39632069-76D91CD5-1804-44AD-AF54-EBC3EF5D2447

P2093

Q39632069-0D976CA2-9D93-4428-8E7A-180B87F189DF

Q39632069-1091C235-4A92-4FC6-B175-46BF2BCB1423

Q39632069-1DE6A29C-A33B-41E4-BA8F-220C3229E663

Q39632069-24A9E0EF-1766-4AB5-9BD4-EE86FCBAEC88

Q39632069-2BD89286-4F86-499B-B367-4383FED46402

Q39632069-30722555-3BE8-40D6-AE88-9090DE023AB3

Q39632069-3DD4214C-B669-427C-A086-925536E4032E

Q39632069-43FBE799-C79E-4080-8E7F-7BD9B802BE89

Q39632069-5148460A-9A11-4FEE-8856-93D5F47D27E1

Q39632069-59AE5764-B977-4844-91CB-25267F52858E

P2860

Q39632069-068C3BB2-8BCC-48ED-9D23-D4FF590E471B

Q39632069-1C354BC3-4808-4717-B64E-5464DF24AEE1

Q39632069-4096B773-8E65-46CE-8246-5E7996A4B069

Q39632069-4636BBAB-C58C-4C19-801B-54ED42E6B84F

Q39632069-4FFFE047-78AF-44EE-8004-560B07538187

Q39632069-55C7DAD3-04C8-4CC9-854C-9EA4BB9CE614

Q39632069-7523FE4F-1C00-4ED2-B523-035D784E2D7A

Q39632069-97357F9B-E0E8-4150-BFAF-CF3A7D177B54

Q39632069-AA81E28E-A7A6-4A5D-AE45-B75663DF24F6

Q39632069-E4CC30EE-BC86-4B23-BA3E-4D8346197CD0

P304

Q39632069-06E6776C-BBC6-4E45-A0AA-CD68CD85C70F

P31

Q39632069-41ECD37D-BC42-4014-9336-ED967256DF45

P356

Q39632069-9C82DC45-6AD3-4595-A8CE-4FEE8C333DF2

P433

Q39632069-A604D867-A532-4F68-8FB0-A30B61CD87A3

P478

Q39632069-15A43526-5C16-4DF0-A7D2-FC6CEAE35BA6

P50

Q39632069-106F041D-8AE1-4059-880C-3188FDD8B6D2

P577

Q39632069-2C1D38F0-09B7-46AA-98D2-F5ECA03BB495

P5875

Q39632069-DF069DB7-207C-41D3-A54E-3E3C7717A2C7

P698

Q39632069-5499A589-1C51-4F42-88C1-74C14964B642

P356

P1433

Arthritis and Rheumatism

P1476

Measuring disease activity and ...... derma and Raynaud's phenomenon

@en

P2093

Arthur Weinstein

http://www.w3.org/2001/XMLSchema#string

Barbara White

http://www.w3.org/2001/XMLSchema#string

Daniel E Furst

http://www.w3.org/2001/XMLSchema#string

David H Collier

http://www.w3.org/2001/XMLSchema#string

Fredrick M Wigley

http://www.w3.org/2001/XMLSchema#string

James R Seibold

http://www.w3.org/2001/XMLSchema#string

Jennifer J Anderson

http://www.w3.org/2001/XMLSchema#string

Joseph H Korn

http://www.w3.org/2001/XMLSchema#string

Karen Herlyn

http://www.w3.org/2001/XMLSchema#string

Mary Ellen Csuka

http://www.w3.org/2001/XMLSchema#string

P2860

Statistical methods for assessing agreement between two methods of clinical measurement

Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.

Depressive symptoms associated with scleroderma.

The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time.

Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.

Predictors of psychosocial adjustment in systemic sclerosis. The influence of formal education level, functional ability, hardiness, uncertainty, and social support.

Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis.

Measuring health status in arthritis. The arthritis impact measurement scales.

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research.

P304

2410-2420

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.10486

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11100992

http://www.w3.org/2001/XMLSchema#string

P698

12355489

http://www.w3.org/2001/XMLSchema#string